Vir and Alnylam Anticipate the Initiation of Clinical Study Assessing VIR-2703 By the Year End

Alnylam Reports Results of Givosiran in P-III ENVISION Study to Treat Acute Hepatic Porphyria


  • The companies reported the selection of DC for VIR-2703 (ALN-COV) targeting SARS-CoV-2 genome and intend to meet US FDA & other regulatory authorities for IND filing with a plan to commence human studies by the end of 2020
  • In Oct, 2017, Alnylam and Vir entered into an exclusive license agreement to develop and commercialize RNAi therapeutics for infectious diseases, with an option to develop up to four additional infectious disease products
  • VIR-2703 is an inhaled siRNA targeting SARS-CoV-2 genome and is the first DC selected in Vir’s expanded collaboration with Alnylam for up to four RNAi potential therapeutics for COVID-19

Click here to­ read full press release/ article | Ref: Businesswire | Image: Alnylam

Related News: Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi Therapeutics Targeting Host Factors for COVID-19